AngioSoma, Inc., a publicly traded Nevada corporation (‘SOAN’), and its subsidiary AngioSoma Research, Inc., a wholly owned Texas subsidiary, own patents associated with the OmniCath® I atherectomy catheter, protected by a U.S. Patent 5,728,129 issued on March 17th, 1998. SOAN is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath® II.
Atherectomy devices help in plaque removal, particularly calcified plaque, by physically drilling, pulverizing or shaving it. This technique is a popular substitute for stents and angioplasty treatments. In stents and angioplasty, the deposited plaque is pushed inside the blood vessel, however in atherectomy the plaque is removed by using surgical methods. This technique has advantages over other methods by providing increased wound healing rate.
Recent recalls of medical devices have been a major issue in the pharmaceutical industry – including hysterectomy power
- plaque is removed from the body through the OmniCath®’s I suction;
- whole device is disposable (expensive though), therefore MRSA cannot infect subsequent patients; and
- bowed wires force the tip of the cutter housing against the laterally against the interior arterial wall.
With subsequent patents being filed by AngioSoma Research, Inc. and Dr. David ‘Doc’ Summers PhD, OmniCath® II will provide:
- a plaque cutting mechanism that allows cutting from either (a) the end-tip to first recanalize the blocked lumen, then (b) a further step of completely debulking the lesion using the directional side-window;
- discrete angioplasty balloon proximal (upstream) to blood flow allowing for second step angioplasty and vessel wall remolding;
- using the same balloon for optional upstream blocking of blood flow allowing simultaneous saline irrigation and clear endoscopic view from the side-cutting window or most distal tip, or for video feed giving the operator/physician precise visual control; and
- completely detachable and disposable catheter shaft, driveline, cutter, and angioplasty balloon from motor assembly preventing cross contamination of infections such as MRSA while allowing reuse of its lithium battery powered motor.
The OmniCath® I is already developed and was before the FDA in 1994 with several working prototypes still existing today! Furthermore, this 510K submission gets an up or down approval within ninety (90) days.
© 2016 by AngioSoma, Inc., all rights reserved.